Overview

Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the change in forced expiratory volume (FEV1) from baseline to Day 28-30 between Cipro Inhale-treated and placebo-treated subjects after a 4-week treatment period.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer
Collaborator:
Novartis
Treatments:
Ciprofloxacin